ANIP

ANI Pharmaceuticals, Inc.

67.41

USD

-2.21

-3.17%

Nov 06, 15:59 UTC -5

Closed

After-Market

67.34

-0.07

-0.10%

ANI Pharmaceuticals, Inc. (ANIP) Profile

ANI Pharmaceuticals, Inc. Profile

About

ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN.

Info & Links

CEO

Nikhil Lalwani

Headquarters

210 Main Street West
Baudette, MN 56623, UNITED STATES

Auditor

EisnerAmper LLP

Share holders

366

Employees

970

ANI Pharmaceuticals, Inc. Statistics

Valuation Measures

Market Capitalization²

1.55B

Enterprise Value

1.73B

Enterprise Value/EBITDA(ttm)

6.95

Price to Earnings Ratio(ttm)

9.93

Price to Sales(ttm)

1.66

Price to Book(mrq)

2.72

Price to Cash(ytd)

7.11

Profitability

Gross Margin(ttm)

45.59%

Operating Margin(ttm)

15.43%

Profit Margin(ttm)

8.21%

Return on Equity(ttm)

27.37%

Return on Invested Capital(ttm)

7.04%

Return on Assets(ttm)

10.47%

Income Statement

Revenue(ttm)

1.04B

Revenue Per Share(ttm)

45.81

Gross Profit(ttm)

635.80M

EBITDA(ttm)³

249.21M

Net Income Available to Common(ttm)

116.84M

Diluted EPS(ttm)

5.02

Share Statistics

Beta (5Y Monthly)

0.45

52-Week Change

-25.29%

S&P 500 52-Week Change

14.03%

S&P 500 Member

Stock Optionable

Yes

Total Shares Outstanding¹

22.73M

Dividend Yield

0.00%

Float⁴

21.11M

% Held by Insiders

8.10%

% Held by Institutions

76.05%

Balance Sheet

Total Cash(mrq)

436.38M

Total Cash Per Share(mrq)

19.20

Total Debt(mrq)

607.23M

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

Quick Ratio(mrq)

2.41%

Book Value Per Share(mrq)

Cash Flow

Operating Cash Flow Per Share(ytd)

Free Cash Flow(ytd)

0.00

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.